Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, visit http://www.kalobios.com.

Contact:

Herb Cross
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3114
ir@kalobios.com

Media Contact:

Joan E. Kureczka
Kureczka/Martin Associates
Tel:  (415) 821-2413
Mobile:  (415) 690-0210
Joan@Kureczka-Martin.com


'/>"/>
SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Cell therapy using patients own bone marrow may present option for heart disease
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Entomology 2012 to present 105 insect symposia in November
4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
5. The Brain Prize 2012 is presented May 9th
6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
9. Coral reef experts to present latest coral reef science during July symposium
10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2014)... the world? Surprisingly, bacteria also face this problem. Theoretical ... how these organisms should decide how best to preserve ... is quite adaptable. It moves about in liquids and ... can stick to an underlying substrate. Actually, the bacteria ...
(Date:4/15/2014)... April 15, 2014, Irvine, Calif. UC Irvine neurobiologists have ... when transplanted into the brains of mice with the symptoms ... in the journal Stem Cells Research and Therapy , ... different mouse models. , Alzheimer,s disease, one of the ...
(Date:4/15/2014)... study of nearly 1,000 mother-child pairs, researchers from the ... to selective serotonin reuptake inhibitors (SSRIs), a frequently prescribed ... with autism spectrum disorder (ASD) and developmental delays (DD) ... of Pediatrics , analyzed data from large samples ...
Breaking Biology News(10 mins):Theoretical biophysics: Adventurous bacteria 2UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2
... be best known for their supersized canines, but they also ... fatal bite, says a new study in the journal ... extinct cat Smilodon fatalis roamed North and South ... as bison, camels, mastodons and mammoths. Telltale clues from bones ...
... While pregnant women may worry about the effects of air ... exposure to carbon monoxide and fine particles in the air ... preterm delivery or preeclampsia -- a serious condition that arises ... headed by a University at Buffalo epidemiologist. , The ...
... cell decide its particular identity? According to biologists at ... of T cellsimmune system cells that help destroy invading ... particular gene called Bcl11b. The activation of Bcl11b ... have decided to go on the T-cell pathway," says ...
Cached Biology News:Why you should never arm wrestle a saber-toothed tiger 2Air pollution doesn't increase risk of preeclampsia, early delivery, study finds 2Caltech biologists discover how T cells make a commitment 2Caltech biologists discover how T cells make a commitment 3
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... United States in ... More Than a Decade, ... in diagnostic imaging, announced today that the U.S. Food,and Drug Administration ... intravenous use in,T1-weighted magnetic resonance imaging (MRI) of the liver to ...
... Board and Management Focused on Near-Term Milestones and Maintain ... ... DIEGO, July 8 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI, OTC: MGIFF), ... requisition for a special meeting of shareholders,for the purpose of ...
... CFO-level financial and management services for technology and biotechnology companies, today ... office. Strickland is the latest partner to join the company's Boston ... ... Cambridge, MA (PRWEB) July 8, 2008 -- TechCFO, a leading ...
Cached Biology Technology:FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 2FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 3FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 4FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 5FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 6FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 7MIGENIX Corporate Update and Requisition of Special Meeting 2MIGENIX Corporate Update and Requisition of Special Meeting 3MIGENIX Corporate Update and Requisition of Special Meeting 4MIGENIX Corporate Update and Requisition of Special Meeting 5MIGENIX Corporate Update and Requisition of Special Meeting 6MIGENIX Corporate Update and Requisition of Special Meeting 7MIGENIX Corporate Update and Requisition of Special Meeting 8TechCFO Adds Gary Strickland as Partner in Boston Office 2
BAFF-R (CT) BR3 Affinity Purified Polyclonal Antibody...
HOXC11 Antibody...
HOXC11 Antibody...
PMM2 Immunogen: PMM2 (NP_000294, 47 a.a. ~ 112 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: